Some preclinical work explores FOXO4-p53-targeting peptides against senescent cancer cells, and the developer has discussed cancer as a research interest, but there is no human evidence that FOXO4-DRI treats cancer
Some researchers use GHK-Cu alongside immunological treatments, providing regenerative support once immune attacks are controlled
No copper monitoring is required for topical-only use, though standard liver function monitoring should continue as part of routine hepatic impairment management
When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1
See GHK-Cu side effects what the research documents (honest, sourced, research-use-only)
posted last year about wanting to weaken FDA oversight of both stem cells and peptides